PT2384326E - Compostos de pirrolo[2,3-d]pirimidina - Google Patents

Compostos de pirrolo[2,3-d]pirimidina Download PDF

Info

Publication number
PT2384326E
PT2384326E PT97868822T PT09786882T PT2384326E PT 2384326 E PT2384326 E PT 2384326E PT 97868822 T PT97868822 T PT 97868822T PT 09786882 T PT09786882 T PT 09786882T PT 2384326 E PT2384326 E PT 2384326E
Authority
PT
Portugal
Prior art keywords
pyrrolo
pyrimidine compounds
pyrimidine
compounds
Prior art date
Application number
PT97868822T
Other languages
English (en)
Inventor
Pamela Jo Berlinski
Matthew Joseph Birchmeier
Jerry Wayne Bowman
Andrea Joy Gonzales
Steven Glenn Kamerling
Donald Wayne Mann
Mark Joseph Mitton-Fry
Original Assignee
Zoetis Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41259411&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2384326(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zoetis Llc filed Critical Zoetis Llc
Publication of PT2384326E publication Critical patent/PT2384326E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
PT97868822T 2008-08-20 2009-08-10 Compostos de pirrolo[2,3-d]pirimidina PT2384326E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9037108P 2008-08-20 2008-08-20

Publications (1)

Publication Number Publication Date
PT2384326E true PT2384326E (pt) 2014-06-09

Family

ID=41259411

Family Applications (1)

Application Number Title Priority Date Filing Date
PT97868822T PT2384326E (pt) 2008-08-20 2009-08-10 Compostos de pirrolo[2,3-d]pirimidina

Country Status (27)

Country Link
US (4) US8133899B2 (pt)
EP (1) EP2384326B1 (pt)
JP (1) JP4884570B2 (pt)
KR (1) KR101335843B1 (pt)
CN (1) CN102131812B (pt)
AR (2) AR073073A1 (pt)
AU (1) AU2009283844B2 (pt)
BR (1) BRPI0917459B1 (pt)
CA (1) CA2733359C (pt)
CL (1) CL2011000353A1 (pt)
CO (1) CO6331437A2 (pt)
DK (1) DK2384326T3 (pt)
EC (1) ECSP11010904A (pt)
ES (1) ES2467109T3 (pt)
HK (1) HK1160116A1 (pt)
HR (1) HRP20140395T1 (pt)
ME (1) ME01269B (pt)
MX (1) MX2011001904A (pt)
NZ (1) NZ605292A (pt)
PL (1) PL2384326T3 (pt)
PT (1) PT2384326E (pt)
RS (1) RS53382B (pt)
RU (1) RU2493157C2 (pt)
SI (1) SI2384326T1 (pt)
UY (1) UY32059A (pt)
WO (1) WO2010020905A1 (pt)
ZA (1) ZA201101701B (pt)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2474545T3 (pl) 2005-12-13 2017-04-28 Incyte Holdings Corporation Podstawione heteroarylem pirolo[2,3-b]pirydyny i pirolo[2,3-b]pirymidyny jako inhibitory kinazy Janusowej
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
HUE043732T2 (hu) 2007-06-13 2019-09-30 Incyte Holdings Corp Januskináz gátló hatású (R)-3-(4-(7H pirrolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il)-3-ciklopentilpropánnitril sók alkalmazása
EA031116B1 (ru) 2009-04-03 2018-11-30 Ф. Хоффманн-Ля Рош Аг КРИСТАЛЛИЧЕСКИЕ ПОЛИМОРФНЫЕ ФОРМЫ {3-[5-(4-ХЛОРФЕНИЛ)-1H-ПИРРОЛО[2,3-b]ПИРИДИН-3-КАРБОНИЛ]-2,4-ДИФТОРФЕНИЛ}АМИДА ПРОПАН-1-СУЛЬФОНОВОЙ КИСЛОТЫ
AU2010249380B2 (en) 2009-05-22 2015-08-20 Incyte Holdings Corporation N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as Janus kinase inhibitors
CA2761954C (en) 2009-05-22 2018-07-31 Incyte Corporation 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors
TW201113285A (en) 2009-09-01 2011-04-16 Incyte Corp Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
JP5629324B2 (ja) 2009-10-15 2014-11-19 ファイザー・インク ピロロ［２，３−ｄ］ピリミジン化合物
MX2012005284A (es) 2009-11-06 2012-06-28 Plexxikon Inc Compuestos y metodos para la modulacion de cinasas. e indicaciones para ello.
JP5739446B2 (ja) * 2009-12-18 2015-06-24 ファイザー・インク ピロロ［２，３−ｄ］ピリミジン化合物
CN102781431B (zh) * 2010-02-24 2014-08-27 硕腾有限责任公司 兽医组合物
AR081315A1 (es) 2010-03-10 2012-08-08 Incyte Corp Derivados heterociclicos de piperidin y pirimidin -4-il-azetidina, una forma cristalina de la sal del acido acetonitriladipico de un derivado pirimidinico, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades relacionadas con la inhibicion de jak-1, t
TWI619713B (zh) 2010-04-21 2018-04-01 普雷辛肯公司 用於激酶調節的化合物和方法及其適應症
NZ603686A (en) 2010-05-21 2014-11-28 Incyte Corp Topical formulation for a jak inhibitor
JP5917544B2 (ja) 2010-11-19 2016-05-18 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｊａｋ阻害剤としての複素環置換ピロロピリジンおよびピロロピリミジン
EA026201B1 (ru) 2010-11-19 2017-03-31 Инсайт Холдингс Корпорейшн Циклобутилзамещенные производные пирролопиридина и пирролопиримидина как ингибиторы jak
PT2672967T (pt) 2011-02-07 2018-12-07 Plexxikon Inc Compostos e métodos de modulação da quinase e suas indicações
CA2832611C (en) 2011-04-12 2019-05-14 Rigel Pharmaceuticals, Inc. Methods for inhibiting allograft rejection
AR086983A1 (es) 2011-06-20 2014-02-05 Incyte Corp Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak
US8790651B2 (en) 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
AR091079A1 (es) 2012-05-18 2014-12-30 Incyte Corp Derivados de pirrolopirimidina y pirrolopiridina sustituida con piperidinilciclobutilo como inhibidores de jak
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
PL2875013T3 (pl) * 2012-07-17 2018-06-29 Glaxosmithkline Intellectual Property (No. 2) Limited Indolokarbonitryle jako selektywne modulatory receptora androgenowego
MX360857B (es) * 2012-07-20 2018-11-20 Zoetis Llc Régimen de dosificación para inhibidores de janus quinasa (jak).
PL2919766T3 (pl) 2012-11-15 2021-10-04 Incyte Holdings Corporation Postacie dawkowania ruksolitynibu o przedłużonym uwalnianiu
CN103896946B (zh) * 2012-12-28 2018-04-03 浙江导明医药科技有限公司 用于预防及治疗多种自身免疫疾病的新化合物
WO2014118388A1 (en) 2013-02-04 2014-08-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for assaying jak2 activity in red blood cells and uses thereof
LT3290421T (lt) * 2013-02-22 2019-02-25 Pfizer Inc. Pirolo [2, 3 -d]pirimidino darinių derinys su vienu arba daugiau papildomų agentų, kaip janus kinazės (jak) inhibitorių
AU2014225938B2 (en) 2013-03-06 2018-07-19 Incyte Holdings Corporation Processes and intermediates for making a JAK inhibitor
US20140343034A1 (en) * 2013-04-25 2014-11-20 Japan Tobacco Inc. Skin barrier function improving agent
MX2016001639A (es) 2013-08-07 2016-10-07 Incyte Corp Formas de dosificacion de liberacion prolongada para un inhibidor de jak 1 (cinasa de janus 1).
EP2924026A1 (en) * 2014-03-28 2015-09-30 Novartis Tiergesundheit AG Aminosulfonylmethylcyclohexanes as JAK inhibitors
WO2015184305A1 (en) 2014-05-30 2015-12-03 Incyte Corporation TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
WO2016024185A1 (en) 2014-08-12 2016-02-18 Pfizer Inc. Pyrrolo[2,3-d]pyrimidine derivatives useful for inhibiting janus kinase
KR101864561B1 (ko) 2015-01-20 2018-06-04 우시 포춘 파마슈티컬 컴퍼니 리미티드 Jak 억제제
UA119701C2 (uk) 2015-04-29 2019-07-25 Вуксі Фортуне Фармасьютікал Ко., Лтд Піримідинові сполуки як jak-інгібітори
JP6564473B2 (ja) 2015-05-29 2019-08-21 无▲錫▼福祈制▲薬▼有限公司Ｗｕｘｉ Ｆｏｒｔｕｎｅ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．，Ｌｔｄ Ｊａｎｕｓキナーゼ阻害剤
WO2017013270A1 (en) 2015-07-23 2017-01-26 Universite De Strasbourg Use of leptin signaling inhibitor for protecting kidneys from patients having ciliopathy
WO2017134212A1 (en) * 2016-02-05 2017-08-10 Siegfried Ag Process for the preparation of trans-4-amino-1-cyclohexanecarboxilic acid and its derivatives
AU2017221193B2 (en) * 2016-02-16 2019-03-14 Zoetis Services Llc Process for preparing 7H-pyrrolo (2, 3-d) pyrimidine compounds
CN107365312B (zh) * 2016-05-13 2021-10-01 瑞博(杭州)医药科技有限公司 一种制备Oclacitinib的新方法
EP3555074B1 (en) 2016-12-14 2022-07-27 Intervet International B.V. Aminopyrazoles as selective janus kinase inhibitors
WO2018156180A1 (en) 2017-02-24 2018-08-30 Kindred Biosciences, Inc. Anti-il31 antibodies for veterinary use
WO2018167283A1 (en) 2017-03-17 2018-09-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma associated neural remodeling
US20200088732A1 (en) 2017-04-13 2020-03-19 INSERM (Institut National de la Santé et de la Recherche Mèdicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma
RU2019142472A (ru) 2017-05-23 2021-06-24 ТЕРЕВАНС БАЙОФАРМА Ар энд Ди АйПи, ЭлЭлСи Глюкуронидные пролекарства ингибиторов янус-киназы
US10596161B2 (en) 2017-12-08 2020-03-24 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
DK3746429T3 (da) 2018-01-30 2022-05-02 Incyte Corp Fremgangsmåder til fremstilling af (1-(3-fluor-2-(trifluormethyl)isonicotinyl)piperidin-4-on)
KR20230145511A (ko) 2018-03-16 2023-10-17 조에티스 서비시즈 엘엘씨 수의학적 용도를 위한 인터류킨-31 단클론성 항체
MA52011A (fr) 2018-03-16 2021-01-20 Zoetis Services Llc Vaccins peptidiques contre l'interleukine-31
UA127925C2 (uk) 2018-03-30 2024-02-14 Інсайт Корпорейшн Лікування гнійного гідраденіту з використанням інгібіторів jak
WO2020092015A1 (en) 2018-11-02 2020-05-07 University Of Rochester Therapeutic mitigation of epithelial infection
JP2022506682A (ja) * 2018-11-05 2022-01-17 アビスタ ファーマ ソリューションズ，インコーポレーテッド 化合物
NL2022471B1 (en) 2019-01-29 2020-08-18 Vationpharma B V Solid state forms of oclacitinib
AU2019426113B2 (en) * 2019-01-30 2022-06-16 Felicamed Biotechnology Co., Ltd. JAK inhibitor and preparation method therefor
MX2022007636A (es) 2019-12-20 2022-07-19 Intervet Int Bv Anticuerpos biespecificos caninizados y pares de union biespecificos para el tratamiento contra dermatitis atopica.
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
CN112279854B (zh) * 2020-08-25 2022-04-05 常州齐晖药业有限公司 一种7H-吡咯并[2,3-d]嘧啶化合物的制备方法
WO2022079139A1 (en) 2020-10-15 2022-04-21 Intervet International B.V. Caninized antibodies to canine interleukin-31 receptor alpha
CN117242080A (zh) 2020-12-18 2023-12-15 勃林格殷格翰动物保健美国公司 含硼吡唑化合物、包括其的组合物、其方法和用途
BR112023016043A2 (pt) 2021-02-22 2023-12-05 Zoetis Services Llc Modelo de prurido induzido por il-31 de cavalo
AU2022331122A1 (en) 2021-08-20 2024-02-15 Intervet International B.V. Homodimer fusion proteins for treating atopic dermatitis
WO2023111128A1 (en) 2021-12-16 2023-06-22 Intervet International B.V. Caninized antibodies to canine interleukin-31 receptor alpha ii
WO2023118555A1 (en) 2021-12-24 2023-06-29 Intervet International B.V. Use of aminopyrazole compounds
CN114605420A (zh) * 2022-04-25 2022-06-10 江苏慧聚药业股份有限公司 一条马来酸奥拉替尼的合成方法

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3037980A (en) 1955-08-18 1962-06-05 Burroughs Wellcome Co Pyrrolopyrimidine vasodilators and method of making them
GB915304A (en) 1958-03-13 1963-01-09 Wellcome Found Pyrrolo[2,3-d]pyrimidine derivatives
US3670079A (en) 1970-10-06 1972-06-13 Merck & Co Inc Anabolic agents
US4997936A (en) 1977-10-19 1991-03-05 Merck & Co., Inc. 2-carbamimidoyl-6-substituted-1-carbadethiapen-2-em-3-carboxylic acids
US4456464A (en) 1982-05-19 1984-06-26 Zoecon Corporation Phenoxy- and pyridyloxy-phenoxyalkyl phosphinates and related sulfur compounds for weed control
US4526608A (en) 1982-07-14 1985-07-02 Zoecon Corporation Certain 2-pyridyloxyphenyl-oximino-ether-carboxylates, herbicidal compositions containing same and their herbicidal method of use
US4590282A (en) 1984-09-24 1986-05-20 Sandoz Ltd. Pest control agents
US4933339A (en) 1985-08-21 1990-06-12 Rohm And Haas Company (2-cyano-2-arylethyl)pyridine compounds useful in controlling fungicidal activity
CA1328333C (en) 1988-03-04 1994-04-05 Quirico Branca Amino acid derivatives
NO169490C (no) 1988-03-24 1992-07-01 Takeda Chemical Industries Ltd Analogifremgangsmaate for fremstilling av terapeutisk aktive pyrrolopyrimidinderivater
US4879309A (en) 1988-09-27 1989-11-07 Schering Corporation Mercapto-acylamino acids as antihypertensives
JP2983254B2 (ja) 1989-06-14 1999-11-29 武田薬品工業株式会社 ピロロ〔２，３―ｄ〕ピリミジン誘導体の製造法およびその中間体
US5356903A (en) 1993-04-22 1994-10-18 Sterling Winthrop Inc. 1-cyclopropyl-4-pyridyl-quinolines
US6136595A (en) 1993-07-29 2000-10-24 St. Jude Children's Research Hospital Jak kinases and regulations of cytokine signal transduction
US5389509A (en) 1993-10-04 1995-02-14 Eastman Kodak Company Ultrathin high chloride tabular grain emulsions
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
ES2109796T3 (es) 1994-05-03 1998-01-16 Ciba Geigy Ag Derivados de pirrolopirimidilo con efecto antiproliferante.
DK0831829T3 (da) 1995-06-07 2003-12-15 Pfizer Heterocykliske, ringkondenserede pyrimidinderivater
US6066638A (en) 1995-07-05 2000-05-23 E. I. Du Pont De Nemours And Company Fungicidal pyrimidinones
TR199800012T1 (xx) 1995-07-06 1998-04-21 Novartis Ag Piroloprimidinler ve preparasyon i�in tatbikler.
AR004010A1 (es) 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
EA000072B1 (ru) 1995-11-14 1998-06-25 Фармация Энд Апджон С.П.А. Бициклическое конденсированное пиримидиновое соединение и его применение в качестве терапевтического агента
WO1997027199A1 (en) 1996-01-23 1997-07-31 Novartis Ag Pyrrolopyrimidines and processes for their preparation
CH690773A5 (de) 1996-02-01 2001-01-15 Novartis Ag Pyrrolo(2,3-d)pyrimide und ihre Verwendung.
GB9604361D0 (en) 1996-02-29 1996-05-01 Pharmacia Spa 4-Substituted pyrrolopyrimidine compounds as tyrosine kinase inhibitors
WO1997032879A1 (de) 1996-03-06 1997-09-12 Novartis Ag 7-ALKYL-PYRROLO[2,3-d]PYRIMIDINE
WO1997049706A1 (en) 1996-06-25 1997-12-31 Novartis Ag SUBSTITUTED 7-AMINO-PYRROLO[3,2-d]PYRIMIDINES AND THE USE THEREOF
ID19430A (id) 1996-07-13 1998-07-09 Glaxo Group Ltd Senyawa senyawa heterosiklik
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
DE69738468T2 (de) 1996-08-23 2009-01-08 Novartis Ag Substituierte pyrrolopyrimidine und verfahren zu ihrer herstellung
KR20000057228A (ko) 1996-11-27 2000-09-15 디. 제이. 우드, 스피겔 알렌 제이 축합된 비사이클릭 피리미딘 유도체
EP0964864B1 (en) 1997-02-05 2008-04-09 Warner-Lambert Company LLC Pyrido 2,3-d pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation
AU6568398A (en) 1997-03-24 1998-10-20 Pharmacia & Upjohn Company Method for identifying inhibitors of jak2/cytokine receptor binding
WO1999051599A1 (en) 1998-04-02 1999-10-14 Neurogen Corporation Aminoalkyl substituted pyrrolo[2,3-b]pyridine and pyrrolo[2,3-d]pyrimidine derivatives: modulators of crf1 receptors
EP1082311A1 (en) 1998-05-28 2001-03-14 Parker Hughes Institute Quinazolines for treating brain tumor
HUP0102574A3 (en) 1998-06-19 2002-01-28 Pfizer Prod Inc Pyrrolo[2,3-d]pyrimidine compounds
PA8474101A1 (es) 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
EP1091739A1 (en) 1998-06-30 2001-04-18 Parker Hughes Institute Method for inhibiting c-jun expression using jak-3 inhibitors
HUP0103386A3 (en) 1998-08-21 2002-07-29 Parker Hughes Inst St Paul Use of quinazoline derivatives for producing pharmaceutical compositions having jak 3-inhibitor effect
ID29028A (id) 1998-09-18 2001-07-26 Basf Ag Pirolopirimidina sebagai penghambat protein kinase
CZ27399A3 (cs) 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
US6080747A (en) 1999-03-05 2000-06-27 Hughes Institute JAK-3 inhibitors for treating allergic disorders
NZ517575A (en) 1999-09-30 2004-04-30 Neurogen Corp Certain alkylene diamine-substituted heterocycles
JP4078074B2 (ja) 1999-12-10 2008-04-23 ファイザー・プロダクツ・インク ピロロ［２，３−ｄ］ピリミジン化合物
ATE323704T1 (de) * 2000-06-26 2006-05-15 Pfizer Prod Inc Pyrrolo¬2,3-däpyrimidin verbindungen als immunosuppressive wirkstoffe
ATE355275T1 (de) 2000-10-20 2006-03-15 Eisai R&D Man Co Ltd Stickstoff-enthaltende aromatische ringverbindungen zur behandlung von tumorerkrankungen
US7301023B2 (en) 2001-05-31 2007-11-27 Pfizer Inc. Chiral salt resolution
GB0119249D0 (en) 2001-08-07 2001-10-03 Novartis Ag Organic compounds
GT200200234A (es) 2001-12-06 2003-06-27 Compuestos cristalinos novedosos
CN1717236A (zh) 2002-11-26 2006-01-04 辉瑞产品公司 治疗移植排斥的方法
US7253166B2 (en) 2003-04-22 2007-08-07 Irm Llc 6-phenyl-7H-pyrrolo[2,3-d]pyrimidine compounds that induce neuronal differentiation in embryonic stem cells
AU2004268621C1 (en) * 2003-08-29 2011-08-18 Exelixis, Inc. c-Kit modulators and methods of use
EP1734967A2 (en) * 2003-12-17 2006-12-27 Pfizer Products Incorporated Pyrrolo [2,3-d] pyrimidine compounds for treating transplant rejection
CA2548951A1 (en) * 2003-12-22 2005-07-14 Gilead Sciences, Inc. Kinase inhibitor phosphonate conjugates
CA2553724A1 (en) * 2004-02-03 2005-08-18 Abbott Laboratories Aminobenzoxazoles as therapeutic agents
JP5368701B2 (ja) * 2004-07-02 2013-12-18 エクセリクシス、インコーポレイテッド ｃ−Ｍｅｔモジュレーター及び使用方法
TW200615268A (en) 2004-08-02 2006-05-16 Osi Pharm Inc Aryl-amino substituted pyrrolopyrimidine multi-kinase inhibiting compounds
AR054416A1 (es) 2004-12-22 2007-06-27 Incyte Corp Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
WO2008089310A2 (en) 2007-01-18 2008-07-24 Lexicon Pharmaceuticals, Inc. Delta 5 desaturase inhibitors for the treatment of obesity
WO2008089307A2 (en) 2007-01-18 2008-07-24 Lexicon Pharmaceuticals, Inc. Delta 5 desaturase inhibitors for the treatment of pain, inflammation and cancer

Also Published As

Publication number Publication date
US9161939B2 (en) 2015-10-20
US20120122901A1 (en) 2012-05-17
KR101335843B1 (ko) 2013-12-02
HK1160116A1 (en) 2012-08-10
AU2009283844A1 (en) 2010-02-25
US20150374701A1 (en) 2015-12-31
MX2011001904A (es) 2011-03-29
JP2012500253A (ja) 2012-01-05
KR20110043697A (ko) 2011-04-27
EP2384326B1 (en) 2014-04-23
JP4884570B2 (ja) 2012-02-29
PL2384326T3 (pl) 2014-09-30
UY32059A (es) 2010-03-26
ECSP11010904A (es) 2011-04-29
NZ605292A (en) 2014-06-27
ZA201101701B (en) 2012-05-30
EP2384326A1 (en) 2011-11-09
HRP20140395T1 (hr) 2014-06-06
CA2733359C (en) 2014-08-05
DK2384326T3 (da) 2014-05-05
RS53382B (en) 2014-10-31
US20150148357A1 (en) 2015-05-28
US8133899B2 (en) 2012-03-13
ME01269B (me) 2013-06-20
AU2009283844B2 (en) 2013-09-05
WO2010020905A1 (en) 2010-02-25
ES2467109T3 (es) 2014-06-11
CN102131812A (zh) 2011-07-20
US20100075996A1 (en) 2010-03-25
RU2493157C2 (ru) 2013-09-20
US9271981B2 (en) 2016-03-01
BRPI0917459B1 (pt) 2017-09-12
CL2011000353A1 (es) 2011-05-06
SI2384326T1 (sl) 2014-06-30
CA2733359A1 (en) 2010-02-25
AR106252A2 (es) 2017-12-27
CN102131812B (zh) 2014-04-09
CO6331437A2 (es) 2011-10-20
BRPI0917459A2 (pt) 2015-12-01
US8987283B2 (en) 2015-03-24
RU2011106331A (ru) 2012-08-27
AR073073A1 (es) 2010-10-13

Similar Documents

Publication Publication Date Title
ZA201101701B (en) Pyrrolo[2,3-d]pyrimidine compounds
ZA201202718B (en) Pyrrolo[2,3-d]pyrimidine compounds
IL278119B (en) Disubstituted pyrazolo[5.1–a]pyrimidine compounds as trk kinase inhibitors
IL257410A (en) Pyrazolo [1, 5 – a ] pyrimidines as antiviral agents
ZA201104853B (en) 2,5-diamino-substituted pyrido[4,3-d]pyrimidines as autotaxin inhibitors against cancer
ZA201002318B (en) Pyrrolo [2,3-d]pyrimidin derivatives as protein kinase b inhibitors
ZA201004368B (en) Pyrazolo [1,5-a] pyrimidines useful as jak2 inhibitors
ZA201004823B (en) Novel pyrazolo [3,4-d]pyrimidine derivatives as anti-cancer agents
EP2525659A4 (en) PYRAZOLO [1,5-A] PYRIMIDINES COMPOUNDS AS MTOR INHIBITORS
ZA201101861B (en) Compositions with and process for methylmorpholin-substituted pyrido [2,3-d] pyrimidines
BRPI0822239A2 (pt) Composto de pirazolo[1,5-a] pirimidina
EP2523552A4 (en) PYRAZOLO- [1,5-A] PYRIMIDINE AS MARK HEMMER
SI2167470T1 (sl) Triazolo(1,5-a)kinolini kot adenozin A3 receptorski ligandi
EP2511276A4 (en) PYRROLO [2,3-D] PYRIMIDINE DERIVATIVE
IL206666A0 (en) N-PHENYLIMIDAZO[1,2-a]PYRIDINE-2-
IL206668A0 (en) N-PHENYLIMIDAZO[1,2-a]PYRIDINE-2-